Alternative approaches to Hsp90 modulation for the treatment of cancer

Future Medicinal Chemistry

Volumn 6, Issue 14, 2014, Pages 1587-1605

  Hall, Jessica A ^a   Forsberg, Leah K ^a   Blagg, Brian S J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ADENOSINE TRIPHOSPHATASE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; CELASTROL; CHAPERONE; DEOXYGLUCOSE; EPIGALLOCATECHIN GALLATE; FK 506 BINDING PROTEIN; GANETESPIB; GEDUNIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; NOVOBIOCIN; OLIGOMYCIN; OXYGEN 17; POTASSIUM CHANNEL HERG; PURINE DERIVATIVE; RADICICOL; RESORCINOL; RETASPIMYCIN; SILIBININ; TANESPIMYCIN; CATECHIN; SILYMARIN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; DIMERIZATION; ENZYME ACTIVITY; NUCLEOTIDE BINDING SITE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION; TETRATRICOPEPTIDE REPEAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; HUMAN; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CATECHIN; DRUG DISCOVERY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; NOVOBIOCIN; SILYMARIN;

EID: 84908571827     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.89     Document Type: Review

References (145)

1. Pratt WB. The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J. Biol Chem. 268(29), 21455-21458 (1993).
2. Csermely P, Schnaider T, SoTi C, Prohászka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 79(2), 129-168 (1998).
3. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11(7), 515-528 (2010).
4. Li J, Soroka J, Buchner J. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones. Biochim. Biophys. Acta 1823(3), 624-635 (2012).
5. Li J, Buchner J. Structure, function and regulation of the Hsp90 machinery. Biomed. J. 36(3), 106-117 (2013).
6. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets 3(5), 301-323 (2003).
7. Panaretou B, Prodromou C, Roe SM et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 17(16), 4829-4836 (1998).
8. Prodromou C, Roe SM, O'brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90(1), 65-75 (1997).
9. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin. Cancer Res. 7(7), 2076-2084 (2001).
10. Chaudhury S, Welch TR, Blagg BSJ. Hsp90 as a target for drug development. Chem. Med. Chem. 1(12), 1331-1340 (2006).
11. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol Chem. 271(37), 22796-22801 (1996).
12. Schneider C, Sepp-Lorenzino L, Nimmesgern E et al. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl Acad. Sci. USA 93(25), 14536-14541 (1996).
13. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 18(1), 64-76 (2012).
14. Da Silva VCH, Ramos CHI. The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: a target for cancer therapeutics. J. Proteomics 75(10), 2790-2802 (2012).
15. Holzbeierlein J, Windsperger A, Vielhauer G. Hsp90: a drug target? Curr. Oncol. Rep. 12(2), 95-101 (2010).
16. Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425(6956), 407-410 (2003).
17. Hadden MK, Lubbers DJ, Blagg BSJ. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr. Top. Med. Chem. 6(11), 1173-1182 (2006).
18. Taldone T, Chiosis G. Purine-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 9(15), 1436-1446 (2009).
19. Kim HR, Kang HS, Kim HD. Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life 48(4), 429-433 (1999).
20. Winklhofer KF, Reintjes A, Hoener MC, Voellmy R, Tatzelt J. Geldanamycin restores a defective heat shock response in vivo. J. Biol Chem. 276(48), 45160-45167 (2001).
21. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of Hsp90 inhibitors. Curr. Cancer Drug Targets 3(5), 349-358 (2003).
22. Ali A, Bharadwaj S, O'carroll R, Ovsenek N. HSP90 interacts with and regulates the activity of heat shock factor 1 in xenopus oocytes. Mol. Cell Biol. 18(9), 4949-4960 (1998).
23. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94(4), 471-480 (1998).
24. Brandt GEL, Blagg BSJ. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr. Top. Med. Chem. 9(15), 1447-1461 (2009).
25. Pearl LH. Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 15(1), 55-61 (2005).
26. Röhl A, Rohrber J, Buchner J. The chaperone Hsp90: changing partners for demanding clients. Trends Biochem. Sci. 38(5), 253-262 (2013).
27. Patwardhan CA, Fauq A, Peterson LB, Miller C, Blagg BSJ, Chadli A. Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis. J. Biol Chem. 288(10), 7313-7325 (2013).
28. Papathanassiu AE, Macdonald NJ, Bencsura A, Vu HA. F1F0-ATP synthase functions as a co-chaperone of Hsp90-substrate protein complexes. Biochem. Biophys. Res. Commun. 345(1), 419-429 (2006).
29. Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 92(3), 242-248 (2000).
30. Kusuma BR, Khandelwal A, Gu W et al. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors. Bioorg. Med. Chem. 22(4), 1441-1449 (2014).
31. Zhao H, Blagg BSJ. Novobiocin analogues with secondgeneration noviose surrogates. Bioorg. Med. Chem. Lett. 23(2), 552-557 (2013).
32. Zhao H, Blagg BSJ. Inhibitors of the Hsp90 C-terminus. In: Inhibitors of Molecular Chaperones as Therapeutic Agents. Machajewski T, Gao Z (Eds). Royal Society of Chemistry, London, UK 259-301 (2013).
33. Prodromou C. The 'active life' of Hsp90 complexes. Biochim. Biophys. Acta 1823(3), 614-623 (2012).
34. Rohl A, Rohrberg J, Buchner J. The chaperone Hsp90: changing partners for demanding clients. Trends Biochem. Sci. 38(5), 253-262 (2013).
35. Li J, Richter K, Reinstein J, Buchner J. Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle. Nat. Struct. Mol. Biol. 20(3), 326-331 (2013).
36. Martinez-Yamout MA, Venkitakrishnan RP, Preece NE, Kroon G, Wright PE, Dyson HJ. Localization of sites of interaction between p23 and Hsp90 in solution. J. Biol Chem. 281(20), 14457-14464 (2006).
37. Mclaughlin SH, Sobott F, Yao Z-P et al. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J. Mol. Biol. 356(3), 746-758 (2006).
38. Connell P, Ballinger CA, Jiang J et al. The co-chaperone CHIP regulates protein triage decisions mediated by heatshock proteins. Nat. Cell Biol. 3(1), 93-96 (2001).
39. Kundrat L, Regan L. Balance between folding and degradation for Hsp90-dependent client proteins: a key role for CHIP. Biochemistry 49(35), 7428-7438 (2010).
40. Murata S, Minami Y, Minami M, Chiba T, Tanaka K. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep. 2(12), 1133-1138 (2001).
41. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. USA 99(20), 12847-12852 (2002).
42. Philp L, Butler M, Hickey T, Butler L, Tilley W, Day T. SGTA. A new player in the molecular co-chaperone game. Horm. Cancer 4(6), 343-357 (2013).
43. Papathanassiu A, Macdonald N, Emlet D, Vu H. Antitumor activity of efrapeptins, alone or in combination with 2-deoxyglucose, in breast cancer in vitro and in vivo. Cell Stress Chaperones 16(2), 181-193 (2011).
44. Dakubo G. The Warburg phenomenon and other metabolic alterations of cancer cells. In: Mitochondrial Genetics and Cancer (Ed). Springer-Verlag Berlin Heidelberg, Berlin, Germany, 39-66 (2010).
45. Capuano F, Guerrieri F, Papa S. Oxidative phosphorylation enzymes in normal and neoplastic cell growth. J. Bioenerg. Biomembr. 29(4), 379-384 (1997).
46. Guppy M, Leedman P, Zu X, Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem. J. 364(1), 309-315 (2002).
47. Wallace DC. Mitochondria and cancer. Nat. Rev. Cancer 12(10), 685-698 (2012).
48. Hall JA, Kusuma BR, Brandt GEL, Blagg BSJ. Cruentaren A. Binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery. ACS Chem. Biol. 9(4), 976-985 (2014).
49. Peng X, Guo X, Borkan SC et al. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. J. Biol Chem. 280(13), 13148-13152 (2005).
50. Zhao R, Davey M, Hsu Y-C et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the Hsp90 chaperone. Cell 120(5), 715-727.
51. Hartson SD, Irwin AD, Shao J et al. p50cdc37 is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules. Biochemistry 39(25), 7631-7644 (2000).
52. Shao J, Irwin A, Hartson SD, Matts RL. Functional dissection of Cdc37: characterization of domain structure and amino acid residues critical for protein kinase binding. Biochemistry 42(43), 12577-12588 (2003).
53. Eckl JM, Rutz DA, Haslbeck V, Zierer BK, Reinstein J, Richter K. Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites. J. Biol Chem. 288(22), 16032-16042 (2013).
54. Gaiser AM, Kretzschmar A, Richter K. Cdc37-Hsp90 complexes are responsive to nucleotide-induced conformational changes and binding of further cofactors. J. Biol Chem. 285(52), 40921-40932 (2010).
55. Zhang M, Kadota Y, Prodromou C, Shirasu K, Pearl LH. Structural basis for assembly of Hsp90-Sgt1-CHORD protein complexes: implications for chaperoning of NLR innate immunity receptors. Mol. Cell 39(2), 269-281 (2010).
56. Eckert K, Saliou J-M, Monlezun L et al. The Pih1-Tah1 cochaperone complex inhibits Hsp90 molecular chaperone ATPase activity. J. Biol Chem. 285(41), 31304-31312 (2010).
57. Silverstein AM, Galigniana MD, Chen M-S, Owens-Grillo JK, Chinkers M, Pratt WB. Protein phosphatase 5 is a major component of glucocorticoid receptor·hsp90 complexes with properties of an FK506-binding immunophilin. J. Biol Chem. 272(26), 16224-16230 (1997).
58. Barent RL, Nair SC, Carr DC et al. Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Mol. Endocrinol. 12(3), 342-354 (1998).
59. Zhang T, Hamza A, Cao X et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7(1), 162-170 (2008).
60. Brandt GEL, Schmidt MD, Prisinzano TE, Blagg BSJ. Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J. Med. Chem. 51(20), 6495-6502 (2008).
61. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction. J. Biol Chem. 284(51), 35381-35389 (2009).
62. Sreeramulu S, Gande SL, Göbel M, Schwalbe H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew. Chem. Int. Ed. Engl. 48(32), 5853-5855 (2009).
63. Chadli A, Felts SJ, Wang Q et al. Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the co-chaperone p23. J. Biol Chem. 285(6), 4224-4231 (2010).
64. Kunze B, Sasse F, Wieczorek H, Huss M. Cruentaren A, a highly cytotoxic benzolactone from Myxobacteria is a novel selective inhibitor of mitochondrial F1-ATPases. FEBS Lett. 581(18), 3523-3527 (2007).
65. Jundt L, Steinmetz H, Luger P et al. Isolation and structure elucidation of cruentarens A and B - novel members of the benzolactone class of ATPase inhibitors from the myxobacterium byssovorax cruenta. European J. Org. Chem. 2006(22), 5036-5044 (2006).
66. Lee JH, Chung IK. Curcumin inhibits nuclear localization of telomerase by dissociating the Hsp90 co-chaperone p23 from hTERT. Cancer Lett. 290(1), 76-86 (2010).
67. Ardi VC, Alexander LD, Johnson VA, Mcalpine SR. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins. ACS Chem. Biol. 6(12), 1357-1366 (2011).
68. Mcconnell JR, Alexander LA, Mcalpine SR. A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. Bioorg. Med. Chem. Lett. 24(2), 661-666 (2014).
69. Vasko RC, Rodriguez RA, Cunningham CN, Ardi VC, Agard DA, Mcalpine SR. Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90. ACS Med. Chem. Lett. 1(1), 4-8 (2010).
70. Grenert JP, Sullivan WP, Fadden P et al. The aminoterminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol Chem. 272(38), 23843-23850 (1997).
71. Roe SM, Prodromou C, O'brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42(2), 260-266 (1999).
72. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim. Biophys. Acta 1823(3), 742-755 (2012).
73. Whitesell L, Lin NU. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim. Biophys. Acta 1823(3), 756-766 (2012).
74. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 14(9), e358-e369 (2013).
75. Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat. Anticancer Drug Discov. 9(1), 1-20 (2014).
76. Kitson RRA, Moody CJ. Learning from nature: advances in geldanamycin- and radicicol-based inhibitors of Hsp90. J. Org. Chem. 78(11), 5117-5141 (2013).
77. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91(18), 8324-8328 (1994).
78. Biamonte MA, Van De Water R, Arndt JW, Scannevin RH, Perret D, Lee W-C. Heat shock protein 90: inhibitors in clinical trials. J. Med. Chem. 53(1), 3-17 (2009).
79. Peterson LB, Eskew JD, Vielhauer GA, Blagg BSJ. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking. Mol. Pharm. 9(6), 1841-1846 (2012).
80. Ficker E, Dennis AT, Wang L, Brown AM. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG. Circ. Res. 92(12), e87-e100 (2003).
81. Duerfeldt AS, Peterson LB, Maynard JC et al. Development of a Grp94 inhibitor. J. Am. Chem. Soc. 134(23), 9796-9804 (2012).
82. Patel PD, Yan P, Seidler PM et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat. Chem. Biol. 9(11), 677-684 (2013).
83. Jeso V, Cherry L, Macklin TK, Pan SC, Lograsso PV, Micalizio GC. Convergent synthesis and discovery of a natural product-inspired paralog-selective Hsp90 inhibitor. Org. Lett. 13(19), 5108-5111 (2011).
84. Hartson SD, Thulasiraman V, Huang W, Whitesell L, Matts RL. Molybdate inhibits Hsp90, induces structural changes in its C-terminal domain and alters its interactions with substrates. Biochemistry 1999(38), 3837-3849 (1999).
85. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275(47), 37181-37186 (2000).
86. Yun B-G, Huang W, Leach N, Hartson SD, Matts RL. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry 43, 8217-8229 (2004).
87. Söti C, Rácz A, Csermely P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J. Biol. Chem. 277(9), 7066-7075 (2002).
88. Garnier C, Lafitte D, Tsvetkov PO et al. Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J. Biol Chem. 277(14), 12208-12214 (2002).
89. Söti C, Vermes Á, Haystead TaJ, Csermely P. Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide affinity cleavage: a distinct nucleotide specificity of the C-terminal ATP-binding site. Eur. J. Biochem. 270(11), 2421-2428 (2003).
90. Cunningham CN, Krukenberg KA, Agard DA. Intra- and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90. J. Biol Chem. 283(30), 21170-21178 (2008).
91. Retzlaff M, Stahl M, Eber HC et al. Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep. 10(10), 1147-1153 (2009).
92. Matts RL, Dixit A, Peterson LB et al. Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem. Biol. 6(8), 800-807 (2011).
93. Ratzke C, Mickler M, Hellenkamp B, Buchner J, Hugel T. Dynamics of heat shock protein 90 C-terminal dimerization is an important part of its conformational cycle. Proc. Natl Acad. Sci. USA 107(37), 16101-16106 (2010).
94. Yu XM, Shen G, Neckers L et al. Hsp90 inhibitor identified from a library of novobiocin analogues. J. Am. Chem. Soc. 127(37), 12778-12779 (2005).
95. Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BSJ. Novobiocin-redesigning a DNA gyrase inhibitor for selective inhibitor of Hsp90. J. Am. Chem. Soc. 128(48), 15529-15536 (2006).
96. Donnelly AC, Mays JR, Burlinson JA et al. The design, synthesis and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J. Org. Chem. 73(22), 8901-8920 (2008).
97. Eskew JD, Sadikot T, Morales P et al. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 11, 468 (2011).
98. Bras GL, Radanyi C, Peyrat J-F et al. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J. Med. Chem. 50(24), 6189-6200 (2007).
99. Radanyi C, Bras GL, Messaoudi S et al. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90). Bioorg. Med. Chem. Lett. 18(7), 2495-2498 (2008).
100. Radanyi C, Bras GL, Marsaud V et al. Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells. Cancer Lett. 274(1), 88-94 (2009).
101. Zhao H, Moroni E, Colombo G, Blagg BSJ. Identification of a new scaffold for Hsp90 C-terminal inhibition. ACS Med. Chem. Lett. 5(1), 84-88 (2014).
102. Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J, Blagg BSJ. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J. Org. Chem. 73(6), 2130-2137 (2008).
103. Peterson LB, Blagg BS. Click chemistry to probe Hsp90: synthesis and evaluation of a series of triazole-containing novobiocin analogues. Bioorg. Med. Chem. Lett. 20(13), 3957-3960 (2010).
104. Gunaherath GMKB, Marron MT, Wijeratne EMK, Whitesell L, Gunatilaka AA. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors. Bioorg. Med. Chem. 21(17), 5118-5129 (2013).
105. Zhao H, Donnelly AC, Kusuma BR et al. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. J. Med. Chem. 54(11), 3839-3853 (2011).
106. Shelton SN, Shawgo ME, Matthews SB et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol. Pharmacol. 76(6), 1314-1322 (2009).
107. Kusuma BR, Duerfeldt AS, Blagg BSJ. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 21(23), 7170-7174 (2011).
108. Donnelly AC, Zhao H, Kusuma BR, Blagg BSJ. Cytotoxic sugar analogues of an optimized novobiocin scaffold. Med. Chem. Commun. 1(2), 165 (2010).
109. Yin Z, Henry EC, Gasiewicz TA. (-)-Epigallocatechin-3-gallate Is a novel Hsp90 inhibitor. Biochemistry 48(2), 336-345 (2009).
110. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother. Res. 24(10), 1423-1432 (2010).
111. Palermo CM, Westlake CA, Gasiewicz TA. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry 44(13), 5041-5052 (2005).
112. Khandelwal A, Hall JA, Blagg BS. Synthesis and structureactivity relationships of EGCG analogues, a recently identified Hsp90 inhibitor. J. Org. Chem. 78(16), 7859-7884 (2013).
113. Lu P, Mamiya T, Lu LL et al. Silibinin attenuates amyloid beta(25-35) peptide-induced memory impairments: implication of inducible nitric-oxide synthase and tumor necrosis factor-alpha in mice. J. Pharmacol. Exp. Ther. 331(1), 319-326 (2009).
114. Zhao H, Brandt GE, Galam L, Matts RL, Blagg BSJ. Identification and initial SAR of silybin: an Hsp90 inhibitor. Bioorg. Med. Chem. Lett. 21(9), 2659-2664 (2011).
115. Zhao H, Yan B, Peterson LB, Blagg BSJ. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. ACS Med. Chem. Lett. 3(4), 327-331 (2012).
116. Mollapour M, Bourboulia D, Beebe K et al. Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATPcompetitive inhibitors. Mol. Cell 53(2), 317-329 (2014).
117. Mollapour M, Neckers L. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim. Biophys. Acta 1823(3), 648-655 (2012).
118. Walton-Diaz A, Khan S, Bourboulia D, Trepel JB, Neckers L, Mollapour M. Contributions of co-chaperones and posttranslational modifications towards Hsp90 drug sensitivity. Future Med. Chem. 5(9), 1059-1071 (2013).
119. Miyata Y. Protein kinase CK2 in health and disease. Cell. Mol. Life Sci. 66(11-12), 1840-1849 (2009).
120. Shao J, Prince T, Hartson SD, Matts RL. Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J. Biol. Chem. 278(40), 38117-38120 (2003).
121. Bandhakavi S, Mccann RO, Hanna DE, Glover CVC. A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases. J. Biol. Chem. 278(5), 2829-2836 (2003).
122. Bansal PK, Mishra A, High AA, Abdulle R, Kitagawa K. Sgt1 dimerization is negatively regulated by protein kinase CK2-mediated phosphorylation at Ser361. J. Biol. Chem. 284(28), 18692-18698 (2009).
123. Kobayashi T, Nakatani Y, Tanioka T et al. Regulation of cytosolic prostaglandin E synthase by phosphorylation. Biochem. J. 381(1), 59-69 (2004).
124. Miyata Y, Chambraud B, Radanyi C et al. Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II. Regulation of HSP90-binding activity of FKBP52. Proc. Natl. Acad. Sci. USA 94(26), 14500-14505 (1997).
125. Yu X, Guo ZS, Marcu MG et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94(7), 504-513 (2002).
126. Nimmanapalli R, Fuino L, Bali P et al. Histone Deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of Imatinib mesylate-sensitive or -refractory Chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63(16), 5126-5135 (2003).
127. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101(8), 3236-3239 (2003).
128. Bali P, Pranpat M, Bradner J et al. Inhibition of Histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280(29), 26729-26734 (2005).
129. Kovacs JJ, Murphy PJM, Gaillard S et al. HDAC6 Regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18(5), 601-607 (2005).
130. Kekatpure VD, Dannenberg AJ, Subbaramaiah K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J. Biol. Chem. 284(12), 7436-7445 (2009).
131. Murphy PJM, Morishima Y, Kovacs JJ, Yao T-P, Pratt WB. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J. Biol. Chem. 280(40), 33792-33799 (2005).
132. Lees-Miller SP, Anderson CW. The human double-stranded DNA-activated protein kinase phosphorylates the 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal threonine residues. J. Biol. Chem. 264(29), 17275-17280 (1989).
133. Old WM, Shabb JB, Houel S et al. Functional proteomics identifies targets of Phosphorylation by B-Raf signaling in melanoma. Mol. Cell 34(1), 115-131 (2009).
134. Barati MT, Rane MJ, Klein JB, Mcleish KR. A proteomic screen identified stress-induced chaperone proteins as targets of Akt phosphorylation in mesangial cells. J. Proteome Res. 5(7), 1636-1646 (2006).
135. Duval M, Le Boeuf F, Huot J, Gratton J-P. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol. Biol. Cell 18(11), 4659-4668 (2007).
136. Lei H, Venkatakrishnan A, Yu S, Kazlauskas A. Protein kinase A-dependent translocation of Hsp90α impairs endothelial nitric-oxide synthase activity in high glucose and diabetes. J. Biol. Chem. 282(13), 9364-9371 (2007).
137. Wang X, Song X, Zhuo W et al. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Mol. Biol. Cell Proc. Natl. Acad. Sci. USA 106(50), 21288-21293 (2009).
138. Lees-Miller SP, Anderson CW. Two human 90-kDa heat shock proteins are phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein kinase II. J. Biol. Chem. 264(5), 2431-2437 (1989).
139. Kurokawa M, Zhao C, Reya T, Kornbluth S. Inhibition of apoptosome formation by suppression of Hsp90β phosphorylation in tyrosine kinase-induced leukemias. Mol. Cell Biol. 28(17), 5494-5506 (2008).
140. Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol. Cell 37(3), 333-343 (2010).
141. Martínez-Ruiz A, Villanueva L, De Orduña CG et al. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Mol. Biol. Cell Proc. Natl. Acad. Sci. USA 102(24), 8525-8530 (2005).
142. Retzlaff M, Stahl M, Eberl HC et al. Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep. 10(10), 1147-1153 (2009).
143. Carbone DL, Doorn JA, Kiebler Z, Ickes BR, Petersen DR. Modification of heat shock protein 90 by 4-Hydroxynonenal in a rat model of chronic alcoholic liver disease. J. Pharmacol. Exp. Ther. 315(1), 8-15 (2005).
144. Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G. Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells Induced with hypericin. Cancer Res. 63(23), 8241-8247 (2003).
145. Murtagh J, Lu H, Schwartz EL. Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation. Cancer Res. 66(16), 8192-8199 (2006).